Clinical Trials Logo

Filter by:
NCT ID: NCT04932551 Recruiting - Asthma Clinical Trials

Perspectives and Management of Atypical Asthma

Start date: January 15, 2021
Phase:
Study type: Observational

To evaluate the awareness/knowledge, clinical practice of atypical asthma among respiratory specialists and primary care practitioners (PCPs) in China.A total of 1166 respiratory specialists and 799 PCPs participated in the questionnaire survey via WeChat. The questionnaire included six major items, divided into physician demographic characteristics, awareness, diagnosis, medication prescription, assessment/education, and proposal.

NCT ID: NCT04932395 Recruiting - Cardiac Neurosis Clinical Trials

Anshen Buxin Liuwei Pills for the Treatment of Cardiac Neurosis

Start date: June 22, 2021
Phase: Phase 4
Study type: Interventional

This study aims to assess the effect and safety of the traditional Mongolian medicine Anshen Buxin Liuwei Pill for the treatment of cardiac neurosis.

NCT ID: NCT04932330 Recruiting - Clinical trials for ICU Acquired Weakness

Risk Factors of ICU-acquired Weakness

ICU-AW
Start date: March 1, 2017
Phase:
Study type: Observational

We conducted a retrospective study of critical ill patients who used ECMO during their ICU stay. ICU-AW was diagnosed at the time when patients discharged and had a Medical Research Council (MRC) sum score < 48 out of a maximal score of 60. We divided patients to ICU-acquired weakness group and no ICU-acquired weakness group and compared their clinical characteristics. Baseline characteristics and therapy details were collected from the case report forms and inspection reports. Univariable analysis and logistic regression analysis were used to analyze clinical characteristics of individuals and to find risk factors of ICU-AW.

NCT ID: NCT04932187 Recruiting - Clinical trials for Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Start date: August 1, 2021
Phase: Phase 1
Study type: Interventional

This is a single center phase 1 trial to observe safety and efficacy of metronomic capecitabine plus PD-L1 antibody camrelizumab to treat hepatobiliary, pancreatic and other gastrointestinal carcinoma (non-stomach, non-esophagi) patients who had disease progression after all standard regimens. This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.

NCT ID: NCT04931654 Recruiting - Gastric Cancer Clinical Trials

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Start date: September 28, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.

NCT ID: NCT04931576 Recruiting - Thyroid Cancer Clinical Trials

No Drainage During Transoral Endoscopic Thyroidectomy Vestibular Approach(TOETVA)

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This study evaluates the viability and safety of no drainage tube placement during transoral endoscopic thyroidectomy vestibular approach in treatment of patients with papillary thyroid carcinoma.

NCT ID: NCT04931550 Recruiting - Heart Failure Clinical Trials

Clinical Study of Impact of Different Pacing Site in Patients

Start date: August 1, 2020
Phase:
Study type: Observational

At present, cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients. With the rapid development of technology, different sites can be chosen to pace, such as right atrial appendage, the atrial septum and the right atrial wall in the atrium, His bundle, left bundle branch area, right ventricular apex, outflow tract, and left ventricular pacing via coronary vein in the ventricle. There are few studies comparing the long-term efficacy and safety of different pacing sites in daily practice. This study aims to observe the efficacy and safety of cardiac pacing at different sites in short and long term, and to compare the advantages and disadvantages of pacing at different sites.

NCT ID: NCT04931537 Recruiting - Biomarker Clinical Trials

Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.

Start date: May 1, 2021
Phase:
Study type: Observational [Patient Registry]

Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD). Albuminuria and estimated glomerular filtration rate (eGFR) are currently recognized clinical indicators for early diagnosis of DN, however, the sensitivity and specificity are unsatisfactory. The early identification and treatment of DKD are conducive to lowering the risk of kidney damage by as much as 50%. Therefore, it is particularly critical to find new biomarkers to reflect the potential DKD lesions in the clinical silent period earlier and more accurately. Therefore, this study intends to analyze the differentially expressed lipids in early DKD, T2DM and healthy adults by mass spectrometry, and verify the related results by larger samples, so as to screen out early markers of DKD and achieve the ultimate goal of clinical application.

NCT ID: NCT04931394 Recruiting - Pancreatic Cancer Clinical Trials

Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer

Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to explore whether adjuvant chemotherapy regimens guided by organoid drug sensitivity test can improve the outcomes of pancreatic cancer. At the same time, this study will evaluate the successful establishment rate of organoid from fresh surgical specimens , and explore the concordance between drug sensitivity test results and patients' treatment response.

NCT ID: NCT04931381 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer

Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to explore whether chemotherapy regimens guided by organoid drug sensitivity test can improve the outcomes of advanced pancreatic cancer. At the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response.